Company: INMB
Filing Date: 2025-06-30
Form Type: 8-K
Source: 0001213900-25-059690
Chunk: 2

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 8-K
Item: Item 9.01
Chunk 2
---
Item 9.01 Financial statements and Exhibits

(d)
Exhibits.

   5.1      Opinion of Sichenzia Ross Ference Carmel LLP                                 
  10.1      Form of Securities Purchase Agreement, dated June 27, 2025                   
  10.2      Form of Placement Agency Agreement, dated June 27, 2025                      
  23.1      Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1)       
  99.1      Press Release, dated June 27, 2025                                           
  99.2      Press Release, dated June 30, 2025                                           
   104      Cover Page Interactive Data File (embedded within the Inline XBRL document)  

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                           INMUNE BIO INC.                               
  Date: June 30, 2025      By:                  /s/ David Moss           
                                                David Moss               
                                                Chief Financial Officer